Health · 1 view
Oral Peptide Shows Durable Efficacy in Ulcerative Colitis
Health 
Story intelligence
Coverage Single outlet Single-outlet story
Views 1 Community interest
Brief read Under 1 min brief 33 words
Summary
(MedPage Today) -- An oral peptide that blocks the interleukin-23 receptor demonstrated durable long-term efficacy in patients with moderately to severely active ulcerative colitis, according to results from the phase IIb ANTHEM-UC trial.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Most patients won't endorse AI medical responses without a clinician's review, study findsContinue reading
- Long-Acting HIV Shot Works Just Fine for Patients With Adherence IssuesContinue reading
- Phenobarbital shows no clear advantage over diazepam for alcohol withdrawal, large study findsContinue reading
- Medicare Advantage plans are shutting down, leaving millions without coverageContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow